ArticleHuman brain mapping2025
Multimodal Neuroimaging-Guided Stratification in Amyotrophic Lateral Sclerosis Reveals Three Disease Subtypes: A Multi-Cohort Analysis.
Article in Human brain mapping, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Potential Roles of Neuroimaging in Motor Neuron Disease.Current neurology and neuroscience reports · 2026Review
- Quantification of amyotrophic lateral sclerosis (ALS) disease accumulation with T1-weighted high-resolution magnetic resonance imaging: validation in an independent cohort.Journal of neurology · 2026Article
- Article
- Multimodal Neuroimaging-Guided Stratification in Amyotrophic Lateral Sclerosis Reveals Three Disease Subtypes: A Multi-Cohort Analysis.Human brain mapping · 2025Article
- Data-driven subtyping and staging of ALS: A multicenter, longitudinal, deformation-based morphometry study.Imaging neuroscience (Cambridge, Mass.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Amyotrophic lateral sclerosis (ALS) is a multisystem disease with marked pathophysiological and clinical heterogeneity, making individual and objective characterization of the degree of disease progression and disease-related subtrajectories challenging. Here, we use in vivo multimodal neuroimaging data and computational models to generate personalized indices of ALS progression and subtrajectory. We used structural and diffusion weighted imaging of 691 participants (58% ALS) from two independent ALS data sets (North American and Utrecht cohorts) to extract regional values of grey matter (DM) density and white matter (WM) microstructural integrity. Contrastive trajectory inference (cTI) allowed us to identify and separate latent, multivariate patterns in neuroimaging features highlighting ALS-associated pathological processes, which were used to generate subject-specific indices of disease progression and subtrajectory. Disease subtrajectories were based on distinct patterns of alterations in neuroimaging data considering subjects at different disease progression levels. The neuroimaging-based, personalized index of disease progression is indicative of clinical symptom severity (North American: p < 0.01 and Utrecht: p < 0.01) and displays alignment with the King's College staging system (p = 0.001 and p = 0.002). Three ALS subtrajectories were identified that displayed distinct alterations in the motor, limbic system, and widespread cortical and subcortical changes that also differed in clinical symptom manifestation. Our analysis has shown that neuroimaging data encodes subject-specific, disease-related patterns that can be leveraged to obtain an in vivo proxy of disease progression and putative disease subtype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.